The U.S. Food and Drug Administration (FDA) has approved a new first-in-class treatment, Auvelity (dextromethorphan-bupropion), for the treatment of agitation associated with Alzheimer’s disease. Auvelity is now the only FDA-approved treatment for Alzheimer’s-related agitation that is not classified as an antipsychotic, according to the Alzheimer’s Association. “For…